OXNARD, Calif., March 16, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”) or (the “company”), a leading disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, nutraceutical and medical foods markets, and developing cannabinoid molecules and new chemical entities (NCEs), today announces it will be an exhibitor at the INTERPHEX 2017 conference on March 21-23 at the Javits Center, 655 W34th Street, New York City. During the conference, the company can be found at Booth #1563.
“INTERPHEX is a nationally recognized conference where top manufacturers and drug development professionals discuss the newest techniques and trends in the industry,” said Wayne Nasby, COO of CURE Pharmaceutical. “The INTERPHEX conference is an integral part of our strategy to identify potential partnerships within the pharmaceutical industry, capitalizing on opportunities to demonstrate our proprietary drug delivery technology and manufacturing capabilities to industry leaders.”
About CURE Pharmaceutical
Headquartered in Oxnard, CA, CURE Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules that it develops and manufactures in its state of the art cGMP facility. CURE leverages novel drug delivery technologies to develop and commercialize new applications of proven therapeutics. Cure partners with pharmaceutical and biotech companies looking for new methods to deliver their proprietary molecules. The technology enables differentiation within large therapeutic categories and potentially improves patient compliance while widening the therapeutic index. CURE Pharmaceutical is traded under the symbol CURR. For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
About INTERPHEX
For the past 38 years, INTERPHEX has been, and continues to be, the premier pharmaceutical, biotechnology, and device development and manufacturing event where you can “Experience Science through Commercialization.” Sponsored by the Parenteral Drug Association (PDA), the event is based in New York and brings over 11,500 global industry professionals and 625+ industry leading suppliers together to “Learn it, Experience it, Procure it” through a unique combination of no cost technical conference, exhibits, demonstrations, workshops, partnering opportunities and networking to leverage quality, efficiency and cost effectiveness in today’s ever-changing global market. INTERPHEX offers annual domestic and international industry events and educational opportunities around the world. Follow INTERPHEX on Facebook, LinkedIn, Instagram, YouTube, and Twitter. IPX Blog continues the learning beyond the show floor. For more information, visit www.INTERPHEX.com.
Forward-looking statements
This press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Contact: Jules Abraham JQA Partners, Inc. 917-885-7378 [email protected]


Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations
Hyundai Motor Shares Surge on Nvidia Partnership Speculation
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S.
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S.
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 



